万春医药(BYSI.US)宣布普那布林又一免疫抗肿瘤临床试验启动，三联免疫抗肿瘤方案用于治疗PD-1单抗耐药迎来首例患者入组
Last Update:
June 4, 2021
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.